Precigen Sees Unusually Large Options Volume (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) was the target of unusually large options trading on Thursday. Stock investors purchased 11,169 call options on the company. This is an increase of approximately 1,645% compared to the average daily volume of 640 call options.

Precigen Stock Up 18.6 %

PGEN stock opened at $1.34 on Friday. Precigen has a twelve month low of $0.65 and a twelve month high of $1.93. The stock’s 50 day moving average is $0.93 and its 200-day moving average is $1.06. The firm has a market capitalization of $392.45 million, a PE ratio of -2.44 and a beta of 1.65.

Analysts Set New Price Targets

PGEN has been the subject of several recent research reports. JMP Securities reissued a “market outperform” rating and issued a $5.00 price target on shares of Precigen in a research note on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and issued a $6.00 price target (up previously from $4.00) on shares of Precigen in a research note on Thursday. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $7.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Iridian Asset Management LLC CT lifted its holdings in Precigen by 82.5% during the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after acquiring an additional 1,706,815 shares during the period. Geode Capital Management LLC lifted its holdings in Precigen by 4.8% during the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after acquiring an additional 149,829 shares during the period. State Street Corp lifted its holdings in Precigen by 1.0% during the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after acquiring an additional 29,253 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Precigen by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after acquiring an additional 127,467 shares during the period. Finally, Renaissance Technologies LLC increased its position in Precigen by 12.4% in the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock worth $1,869,000 after buying an additional 130,500 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.